These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 28376088)

  • 1. The temporal dynamics of chromosome instability in ovarian cancer cell lines and primary patient samples.
    Penner-Goeke S; Lichtensztejn Z; Neufeld M; Ali JL; Altman AD; Nachtigal MW; McManus KJ
    PLoS Genet; 2017 Apr; 13(4):e1006707. PubMed ID: 28376088
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chromosome instability is prevalent and dynamic in high-grade serous ovarian cancer patient samples.
    Morden CR; Farrell AC; Sliwowski M; Lichtensztejn Z; Altman AD; Nachtigal MW; McManus KJ
    Gynecol Oncol; 2021 Jun; 161(3):769-778. PubMed ID: 33714608
    [TBL] [Abstract][Full Text] [Related]  

  • 3. FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patients.
    Tassi RA; Todeschini P; Siegel ER; Calza S; Cappella P; Ardighieri L; Cadei M; Bugatti M; Romani C; Bandiera E; Zanotti L; Tassone L; Guarino D; Santonocito C; Capoluongo ED; Beltrame L; Erba E; Marchini S; D'Incalci M; Donzelli C; Santin AD; Pecorelli S; Sartori E; Bignotti E; Odicino F; Ravaggi A
    J Exp Clin Cancer Res; 2017 May; 36(1):63. PubMed ID: 28482906
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Blocking Mitotic Exit of Ovarian Cancer Cells by Pharmaceutical Inhibition of the Anaphase-Promoting Complex Reduces Chromosomal Instability.
    Raab M; Sanhaji M; Zhou S; Rödel F; El-Balat A; Becker S; Strebhardt K
    Neoplasia; 2019 Apr; 21(4):363-375. PubMed ID: 30851646
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chromosomal instability confers intrinsic multidrug resistance.
    Lee AJ; Endesfelder D; Rowan AJ; Walther A; Birkbak NJ; Futreal PA; Downward J; Szallasi Z; Tomlinson IP; Howell M; Kschischo M; Swanton C
    Cancer Res; 2011 Mar; 71(5):1858-70. PubMed ID: 21363922
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterizing the prevalence of chromosome instability in interval colorectal cancer.
    Cisyk AL; Penner-Goeke S; Lichtensztejn Z; Nugent Z; Wightman RH; Singh H; McManus KJ
    Neoplasia; 2015 Mar; 17(3):306-16. PubMed ID: 25810015
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Specific Mechanisms of Chromosomal Instability Indicate Therapeutic Sensitivities in High-Grade Serous Ovarian Carcinoma.
    Tamura N; Shaikh N; Muliaditan D; Soliman TN; McGuinness JR; Maniati E; Moralli D; Durin MA; Green CM; Balkwill FR; Wang J; Curtius K; McClelland SE
    Cancer Res; 2020 Nov; 80(22):4946-4959. PubMed ID: 32998996
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inflammation-regulating factors in ascites as predictive biomarkers of drug resistance and progression-free survival in serous epithelial ovarian cancers.
    Lane D; Matte I; Garde-Granger P; Laplante C; Carignan A; Rancourt C; Piché A
    BMC Cancer; 2015 Jul; 15():492. PubMed ID: 26122176
    [TBL] [Abstract][Full Text] [Related]  

  • 9. RUNX3 contributes to carboplatin resistance in epithelial ovarian cancer cells.
    Barghout SH; Zepeda N; Vincent K; Azad AK; Xu Z; Yang C; Steed H; Postovit LM; Fu Y
    Gynecol Oncol; 2015 Sep; 138(3):647-55. PubMed ID: 26186909
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differential cellular responses induced by dorsomorphin and LDN-193189 in chemotherapy-sensitive and chemotherapy-resistant human epithelial ovarian cancer cells.
    Ali JL; Lagasse BJ; Minuk AJ; Love AJ; Moraya AI; Lam L; Arthur G; Gibson SB; Morrison LC; Werbowetski-Ogilvie TE; Fu Y; Nachtigal MW
    Int J Cancer; 2015 Mar; 136(5):E455-69. PubMed ID: 25227893
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A KRAS variant is a biomarker of poor outcome, platinum chemotherapy resistance and a potential target for therapy in ovarian cancer.
    Ratner ES; Keane FK; Lindner R; Tassi RA; Paranjape T; Glasgow M; Nallur S; Deng Y; Lu L; Steele L; Sand S; Muller RU; Bignotti E; Bellone S; Boeke M; Yao X; Pecorelli S; Ravaggi A; Katsaros D; Zelterman D; Cristea MC; Yu H; Rutherford TJ; Weitzel JN; Neuhausen SL; Schwartz PE; Slack FJ; Santin AD; Weidhaas JB
    Oncogene; 2012 Oct; 31(42):4559-66. PubMed ID: 22139083
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A critical role of Oct4A in mediating metastasis and disease-free survival in a mouse model of ovarian cancer.
    Samardzija C; Luwor RB; Volchek M; Quinn MA; Findlay JK; Ahmed N
    Mol Cancer; 2015 Aug; 14():152. PubMed ID: 26260289
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A living biobank of ovarian cancer ex vivo models reveals profound mitotic heterogeneity.
    Nelson L; Tighe A; Golder A; Littler S; Bakker B; Moralli D; Murtuza Baker S; Donaldson IJ; Spierings DCJ; Wardenaar R; Neale B; Burghel GJ; Winter-Roach B; Edmondson R; Clamp AR; Jayson GC; Desai S; Green CM; Hayes A; Foijer F; Morgan RD; Taylor SS
    Nat Commun; 2020 Feb; 11(1):822. PubMed ID: 32054838
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SERPINB3 in the chicken model of ovarian cancer: a prognostic factor for platinum resistance and survival in patients with epithelial ovarian cancer.
    Lim W; Kim HS; Jeong W; Ahn SE; Kim J; Kim YB; Kim MA; Kim MK; Chung HH; Song YS; Bazer FW; Han JY; Song G
    PLoS One; 2012; 7(11):e49869. PubMed ID: 23185467
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacological Inhibition of p38 MAPK by SB203580 Increases Resistance to Carboplatin in A2780cp Cells and Promotes Growth in Primary Ovarian Cancer Cells.
    Han X; Chen H; Zhou J; Steed H; Postovit LM; Fu Y
    Int J Mol Sci; 2018 Jul; 19(8):. PubMed ID: 30049957
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Poly(ADP-ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer.
    Tattersall A; Ryan N; Wiggans AJ; Rogozińska E; Morrison J
    Cochrane Database Syst Rev; 2022 Feb; 2(2):CD007929. PubMed ID: 35170751
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Let-7e sensitizes epithelial ovarian cancer to cisplatin through repressing DNA double strand break repair.
    Xiao M; Cai J; Cai L; Jia J; Xie L; Zhu Y; Huang B; Jin D; Wang Z
    J Ovarian Res; 2017 Apr; 10(1):24. PubMed ID: 28376831
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Distinct patterns of structural and numerical chromosomal instability characterize sporadic ovarian cancer.
    Bayani J; Paderova J; Murphy J; Rosen B; Zielenska M; Squire JA
    Neoplasia; 2008 Oct; 10(10):1057-65. PubMed ID: 18813350
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Specific point mutations in key redox enzymes are associated with chemoresistance in epithelial ovarian cancer.
    Fletcher NM; Belotte J; Saed MG; Memaj I; Diamond MP; Morris RT; Saed GM
    Free Radic Biol Med; 2017 Jan; 102():122-132. PubMed ID: 27890641
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Survival and prognostic factors in patients with recurrent low-grade epithelial ovarian cancer: An analysis of five prospective phase II/III trials of NOGGO metadata base.
    Canaz E; Grabowski JP; Richter R; Braicu EI; Chekerov R; Sehouli J
    Gynecol Oncol; 2019 Sep; 154(3):539-546. PubMed ID: 31230821
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.